Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in South Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 14 | 848 | 23% |
| 2020 | 11 | 713 | 25% |
| 2021 | 12 | 713 | 28% |
| 2022 | 11 | 606 | 32% |
| 2023 | 12 | 565 | 36% |
| 2024 | 11 | 440 | 39% |
| 2025 from claims | – | 407 329–478 | 41% |
| 2026 forecast | – | 430 337–540 | 39% |
| 2027 forecast | – | 436 323–576 | 39% |
| 2028 forecast | – | 442 313–611 | 39% |
| 2029 forecast | – | 449 305–643 | 40% |
| 2030 forecast | – | 455 298–676 | 40% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 95% of the cases CMS names in South Dakota; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 90% hospital outpatient, 10% office.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~430 | ~380 | ~9 | ~37 |
| 2027 · ~440 | ~390 | ~14 | ~35 |
| 2028 · ~440 | ~390 | ~16 | ~33 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 4% (0% in 2025), office about 8% (10% in 2025), hospital outpatient about 89% (90% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 87 | 7,931−11%/yr | −11%/yr | 5.9 | 73% | 7,380 in 2030−1.2%/yr |
| Michigan | 59 | 5,586−14%/yr | −14%/yr | 6.9 | 71% | 4,770 in 2030−2.6%/yr |
| Ohio | 46 | 4,014−15%/yr | −15%/yr | 3.8 | 68% | 3,930 in 2030−0.4%/yr |
| Indiana | 35 | 3,475−14%/yr | −14%/yr | 5.1 | 60% | 2,970 in 2030−2.6%/yr |
| Missouri | 31 | 2,606−17%/yr | −17%/yr | 4.4 | 32% | 2,570 in 2030−0.2%/yr |
| Wisconsin | 23 | 2,016−15%/yr | −15%/yr | 3.7 | 42% | 1,940 in 2030−0.6%/yr |
| Kansas | 17 | 1,438−10%/yr | −10%/yr | 3.6 | 63% | 1,570 in 2030+1.4%/yr |
| Minnesota | 31 | 1,328−18%/yr | −18%/yr | 3.1 | 42% | 1,660 in 2030+3.8%/yr |
| Iowa | 15 | 691−12%/yr | −12%/yr | 1.6 | 11% | 760 in 2030+1.5%/yr |
| Nebraska | 7 | 526−11%/yr | −11%/yr | 2.1 | 3% | 610 in 2030+2.4%/yr |
| North Dakota | 8 | 392−7.1%/yr | −7.1%/yr | 4.0 | 0% | 350 in 2030−1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 13 | 1,501−0.4%/yr | −0.4%/yr | 11.22.8× | 76% | 1,800 in 2030+3%/yr |
| Superficial venous ablation | 12 | 721+12%/yr | +12%/yr | 5.41.6× | 92% | 1,130 in 2030+7.8%/yr |
| Thrombectomy, IVC filters & venous stents | 6 | 318+3.2%/yr | +3.2%/yr | 2.51.7× | 0% | 220 in 2030−5.7%/yr |
| Carotid revascularization | 10 | 315+2.9%/yr | +2.9%/yr | 2.42.1× | 0% | 470 in 2030+6.9%/yr |
Dialysis access in every state, and its device makers · Every procedure market in South Dakota · Every state · Compare with Illinois
BD leads with 100% of company spending on these surgeons in 2025, +98 pts on 2024.
In 2025, 1 company reported engagement with South Dakota’s surgeons worth $68 in consulting, speaking, meals and travel tied to these products, about $6 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.